Related Experiment Video

Updated: Oct 1, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

[Serratia marcescens vaccine in the treatment of malignant pleural effusion]

Heling Shi1, Yunzhong Zhu, Liyan Xu

  • 1Beijing Thoracic Tumour and Tuberculosis Hospital, Beijing 101149, China.

Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|May 17, 2002
PubMed
Abstract

Insights

Serratia marcescens (S311) vaccine shows high efficacy in treating malignant pleural effusion, with a 97.1% response rate. The treatment demonstrated tolerable systemic toxicity, warranting further investigation.

Area of Science:

  • Oncology
  • Immunology
  • Microbiology

Context:

  • Malignant pleural effusion (MPE) presents a significant challenge in cancer care.
  • Current treatment options for MPE have limitations in efficacy and patient tolerance.

Purpose:

  • To assess the therapeutic efficacy and safety profile of Serratia marcescens (S311) vaccine in patients with MPE.
  • To determine the response rates and types of toxicity associated with S311 intrapleural administration.

Summary:

  • A study involving 34 MPE patients administered S311 vaccine via intrapleural injection (10(9) U) on days 1, 8, and 15.
  • Observed a high overall response rate of 97.1% (12 complete responses, 21 partial responses) over a four-week period.
  • Mild systemic toxicities were noted, including fever (82.4%), pleuritic pain (50.7%), nausea (26.5%), dyspnea (17.5%), and chills (5.9%).

Impact:

  • Serratia marcescens (S311) vaccine demonstrates significant potential as an effective treatment for malignant pleural effusion.
  • The vaccine offers a favorable safety profile with manageable side effects, suggesting it as a viable therapeutic option.
  • These findings support further clinical research to establish S311 vaccine's role in oncology supportive care.

More Related Videos

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Rocky Mountain Spotted Fever01:26

Rocky Mountain Spotted Fever

Rocky Mountain Spotted Fever (RMSF) is a severe tick-borne illness caused by Rickettsia rickettsii, a Gram-negative, coccobacillary bacterium. This pathogen is an obligate intracellular parasite, requiring a host cell for replication. Transmission occurs through the bite of an infected tick. In the United States, the most important vectors are Dermacentor variabilis (American dog tick) and Dermacentor andersoni (Rocky Mountain wood tick), though other tick species may also serve as vectors.